| Biomarker ID | 1602 |
| PMID | 26268996 |
| Year | 2015 |
| Biomarker | Vascular endothelial growth factor A (VEGF-A) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.51 (95% CI: 1.08-2.10) |
| Effect on Pathways | Pathway include: Response to elevated platelet cytosolic Ca2+; Development VEGF signaling via VEGFR2 - generic cascades; VEGF Pathway (Qiagen); CDK-mediated phosphorylation and removal of Cdc6; RET signaling |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 535 patients with Prostate Cancer were included in the study out of which 170 experienced Biochemical Recurrence |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.016 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |